A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Leo Pharma Investigational site, Birmingham, Alabama, United States

  • Leo Pharma Investigational site, North Little Rock, Arkansas, United States

  • Leo Pharma Investigational site, Palo Alto, California, United States

  • Leo Pharma Investigational site, Sacramento, California, United States

  • Leo Pharma Investigational site, San Diego, California, United States

  • Leo Pharma Investigational site, San Diego, California, United States

  • Leo Pharma Investigational site, Jacksonville, Florida, United States

  • Leo Pharma Investigational site, Miami, Florida, United States

  • Leo Pharma Investigational site, Tampa, Florida, United States

  • Leo Pharma Investigational site, Macon, Georgia, United States

  • Leo Pharma Investigational site, Waterford, Michigan, United States

  • Leo Pharma Investigational site, Tulsa, Oklahoma, United States

  • Leo Pharma Investigational site, Portland, Oregon, United States

  • Leo Pharma Investigational site, Charleston, South Carolina, United States

  • Leo Pharma Investigational site, Norfolk, Virginia, United States

  • Leo Pharma Investigational site, Brussels, Belgium

  • Leo Pharma Investigational site, Ghent, Belgium

  • Leo Pharma Investigational site, Leuven, Belgium

  • Leo Pharma Investigational site, Liège, Belgium

  • Leo Pharma Investigational site, Burlington, Canada

  • Leo Pharma Investigational site, Calgary, Canada

  • Leo Pharma Investigational site, Calgary, Canada

  • Leo Pharma Investigational site, Edmonton, Canada

  • Leo Pharma Investigational site, Edmonton, Canada

  • Leo Pharma Investigational site, Hamilton, Canada

  • Leo Pharma Investigational site, Niagara Falls, Canada

  • Leo Pharma Investigational site, Saskatoon, Canada

  • Leo Pharma Investigational site, Windsor, Canada

  • Leo Pharma Investigational site, Winnipeg, Canada

  • Leo Pharma Investigational site, Rijeka, Croatia

  • Leo Pharma Investigational site, Zagreb, Croatia

  • Leo Pharma Investigational site, Zagreb, Croatia

  • Leo Pharma Investigational site, Buxtehude, Germany

  • Leo Pharma Investigational site, Dresden, Germany

  • Leo Pharma Investigational site, Mainz, Germany

  • Leo Pharma Investigational site, Osnabrück, Germany

  • Leo Pharma Investigational site, Tübingen, Germany

  • Leo Pharma Investigational site, Wuppertal, Germany

  • Leo Pharma Investigational site, Cork, Ireland

  • Leo Pharma Investigational site, Crumlin, Ireland

  • Leo Pharma Investigational site, Ancona, Italy

  • Leo Pharma Investigational site, Brescia, Italy

  • Leo Pharma Investigational site, Padova, Italy

  • Leo Pharma Investigational site, Roma, Italy

  • Leo Pharma Investigational site, Rome, Italy

  • Leo Pharma Investigational site, Utrecht, Netherlands

  • Leo Pharma Investigational site, Gdansk, Poland

  • Leo Pharma Investigational site, Krakow, Poland

  • Leo Pharma Investigational site, Lodz, Poland

  • Leo Pharma Investigational site, Ostrowiec Świętokrzyski, Poland

  • Leo Pharma Investigational site, Rzeszów, Poland

  • Leo Pharma Investigational site, Tarnów, Poland

  • Leo Pharma Investigational site, Warsaw, Poland

  • Leo Pharma Investigational site, Warsaw, Poland

  • Leo Pharma Investigational site, Brasov, Romania

  • Leo Pharma Investigational site, Iași, Romania

  • Leo Pharma Investigational site, Ansan-si, South Korea

  • Leo Pharma Investigational site, Gwangju, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Seoul, South Korea

  • Leo Pharma Investigational site, Alicante, Spain

  • Leo Pharma Investigational site, Madrid, Spain

  • Leo Pharma Investigational site, Valencia, Spain

  • Leo Pharma Investigational site, Lincoln, United Kingdom

  • Leo Pharma Investigational site, London, United Kingdom

  • Leo Pharma Investigational site, Sheffield, United Kingdom

  • Leo Pharma Investigational site, Southampton, United Kingdom

Study leads
  • Medical Expert

    Study Director

    LEO Pharma